Introduction
============

Killer cell immunoglobulin-like receptor (KIR), expressed by natural killer (NK) cells and certain T cells, is a type of CD158 glucoprotein ([@b1-etm-05-01-0300]). Through the recognition of human leukocyte antigen (HLA)-I, KIR regulates the cytoactivity of the effector cell, begins the immunological process and regulates cytokine secretion. KIR gene clusters have extremely complex gene structures gradually formed from the single gene structure of KIR3DX1 ([@b2-etm-05-01-0300]). The human KIR gene cluster contains fifteen genes and two silencers. The KIR gene cluster encoding the receptor contains protein guide sequences (exons 1 and 2), the extracellular domain (exons 3--5), stem (exon 6), transmembrane domain (exon 7) and intracellular domain (exons 8 and 9). The KIR gene cluster genes are named according to their extracellular domain and intracellular domain structural features. An extracellular domain with two similar immunoglobulin domains would be named 2D, or 3D if it had three similar immunoglobulin domains. KIR genes with longer intracellular domains and transduction inhibitory signals are designated L, while those with shorter intracellular domains and transduction activition signals are designated S. The main ligand of KIR is the HLA-I class antigen. Following the recognition of various HLAs, the KIR receptor determines whether the object belongs to the 'self' or not, thus making it extremely important in immune regulation ([@b3-etm-05-01-0300],[@b4-etm-05-01-0300]). The KIRs may be divided into two categories: stimulatory KIRs (sKIRs) and inhibitory KIRs (iKIRs).

The specific receptors of certain inhibitory KIR class HLA-I molecules are already known. The ligand of the inhibitory genes KIR2DL1, -2DL2 and -2DL3 is HLA-C. Based on the amino acid combination at the heavy chain loci 80, HLA-C has been divided into two groups. In the HLA-C1 group, the amino acid of site 80 is lysine, while in the HLA-C2 group it is aspartic acid. The ligand of KIR2DL1 is HLA-C2 and the ligand of KIR2DL2/2DL3 is HLA-C1 ([@b5-etm-05-01-0300]). KIR2DL1+HLA-C2 combined excitatory and inhibitory signals are stronger than those of KIR2DL2/2DL3+HLA-C1 ([@b6-etm-05-01-0300]). The ligand of KIR3DL1/S1 is the HLA-B antigen which contains a Bw4 structure. It has been reported that KIR3DL1/S1 is able to combine with the HLA-A antigen, which also contains a Bw4 structure ([@b7-etm-05-01-0300]). The ligand of KIR3DL2 is HLA-A3 or HLA-A11. The ligand of KIR2DL4 is HLA-G. The ligand of KIR2DS1-5, an activating gene of KIR, may be an HLA class I antigen although there is no direct evidence to support this theory. Individuals with variations in the KIR gene cluster number and type may be divided into the haploid A and B subtypes, according to its haploid configuration. Haploid A contains frame gene KIR2DL1, KIR2DL3, KIR3DL1 suppressor gene, and KIR2DS4 activating gene. Other configurations are collectively referred to as haploid B. Haploid B contains a number of activating genes.

HLA-Cw is distributed widely in human tissue cells, specifically recognized by KIR and involved in the regulation of NK cell function, which is the basis of NK cell recognition of self and non-self molecules. When the same HLA-Cw molecule is combined with different KIRs, it produces different signals to activate or inhibit the killing function of the NK cells ([@b8-etm-05-01-0300]). Observations have revealed that there are differences between individuals in the combined forms of HLA-Cw and sKIR or iKIR, which not only affect susceptibility to disease ([@b9-etm-05-01-0300]) but also disease progression ([@b10-etm-05-01-0300]). In order to understand the method of the recognition of HLA-Cw and KIR in a Chinese population, the KIR and its HLA-Cw ligands of 154 normal Han individuals from Jilin were examined by PCR-SSP and the identification of HLA-Cw and KIR was analyzed, to provide a the theoretical basis for future research concerning its role in disease progression.

Materials and methods
=====================

Objective of the study
----------------------

A total of 154 normal specimens were selected from unpaid blood donors from a Jilin Han population. This group contained 84 males and 70 females (no blood relations) aged between 21 and 50 years old. Venous blood (5 ml) was obtained, placed in test tubes containing EDTA anticoagulants and stored in a −80°C refrigerator. The experimental protocol was established according to the guidelines of the Declaration of Helsinki and was approved by Human Ethics Committee of Jilin University. Informed consent was obtained from each subject prior to their inclusion in the study.

Genomic DNA extraction
----------------------

Using the TIANamp Blood DNA kit (Tiangen Biotech Beijing Co. Ltd., Beijing, China), genomic DNA was extracted according to the manufacturer's instructions. The DNA concentration was ≥80 mg/l and the purity was A~260~/~280~ = 1.65--1.90.

Primer synthesis
----------------

A previously published method for synthesizing the amplified KIR genes using PCR-SSP genotyping primers ([Table I](#t1-etm-05-01-0300){ref-type="table"}) was used ([@b11-etm-05-01-0300]). The internal control primers of reactions 1 to 15 were FGH (5′-GCCTTCCCAACCATTCCCTTA-3′) and RGH (5′-TCACGGATTTCTGTTGTGTTTC-3′). The length of the amplification product was 429 bp; the internal contrast primers of reaction 16 were DRB1-F (5′-TGCCAAGTGGAGCACCCAA-3′) and DRB1-R (5′-GCATCTTGCTCTGTGCAGAT-3′) and the length of the amplification products was 796 bp. The primers of the HLA-Cw gene for PCR-SSP genotyping were in accordance with those of Mandelboim *et al*([@b5-etm-05-01-0300]). The primers are shown in [Table II](#t2-etm-05-01-0300){ref-type="table"}. All primers were synthesized by Beijing DingGuo ChangSheng Biotechnology Co., Ltd. (Beijing, China) and verified by BLAST.

KIR genes and the HLA-Cw PCR-SSP classification
-----------------------------------------------

Each KIR gene required two pairs of KIR gene primers (upstream and downstream) plus an internal contrast primer system. The HLA-Cw gene also required upstream and downstream primers and an internal contrast primer system.

To amplify KIR genes by PCR-SSP ([@b12-etm-05-01-0300]), 1 μl of each primer mix (5 μM) was dispensed into separate wells in 384-well plates. Each sample required two vertical rows of wells but KIR2DS1 and KIR3DP1 required only one well. PCR cocktails were prepared for each sample with a total volume of 132 μl (enough for 33 reactions) as follows: 200 ng DNA, 16.5 μl 10X PCR buffer (final concentration, 1X), 4.95 μl MgCl~2~ (final concentration 1.5mM), 1.32 μl dNTP (final concentration 200 mM) and 0.825 μl *Taq* polymerase. PCR cocktail (4 μl) was added to each primer mix (total PCR volume = 5 μl). The samples were amplified using a programmable thermal cycler with a heated lid using the following parameters: 3 min at 94°C, 5 cycles of 15 sec at 94°C, 15 sec at 65°C and 30 sec at 72°C; 21 cycles of 15 sec at 94°C, 15 sec at 60°C and 30 sec at 72°C; 4 cycles of 15 sec at 94°C, 1 min at 55°C and 2 min at 72°C with a final 7-min extension step at 72°C.

The HLA-Cw genes were amplified using PCR-SSP genotyping ([@b12-etm-05-01-0300]). The PCR system was as follows: In each reaction, 100 ng of genomic DNA was amplified in 15 μl of 1X PCR master mix \[67 mM Tris-HCl, pH 8.8, 16.6 mM (NH~4~)~2~SO~4~, 0.1% Tween-20, 2 mM MgCl~2~, 200 mM dNTP\] containing specific (0.1--0.8 μm) and control primers, as well as 0.5 units *Taq* polymerase. PCR conditions were: 2 min at 94°C, 10 cycles of 10 sec at 94°C and 60 sec at 65°C; 20 cycles of 10 sec at 94°C, 50 sec at 61°C and 30 sec at 72°C with a final 10-min extension step at 72°C.

Gel electrophoresis
-------------------

The amplification products (5 μl) were electrophoresed on 2% agarose gels with a migration distance of ∼3 cm and stained with ethidium bromide. The amplification was evaluated on a UV transilluminator and photographed.

Analysis of the recognition of HLA-Cw and KIR
---------------------------------------------

The difference in the method of recognition between various HLA-Cws and KIRs depended on the 80th amino acid residues of the HLA-Cw. If the residue was lysine (Lys; HLA-Cw2^Lys80^), the receptor was KIR2DL1/S1. If the residue was asparagine (Asn; HLA-Cw1^Asn80^), the receptor was KIR2DL2/L3/S2. The amino acid sequence was acquired according to the HLA-Cw classification results. By combining this information with the phenotype of the KIR, separate HLA-Cw and KIR recognition statistics could be analyzed.

Statistical analysis
--------------------

The statistical analysis followed that of Martin and Carrington ([@b11-etm-05-01-0300]) and also included the frequency and genotype frequency of HLA-Cw and KIR in the Han population of Jilin. The KIR gene-frequency (F) was measured by direct counting, the phenotype frequency (pf; %) = total number of positive gene/total nu,ber of research group; the KIR gene frequency was calculated as F = 1−√(1−pf).

Results
=======

Electrophoresis of the KIR gene
-------------------------------

Electrophoretic analysis following the conventional amplification of the KIR gene revealed that the size of the target fragment was consistent with the expected results ([Fig. 1](#f1-etm-05-01-0300){ref-type="fig"}).

Electrophoresis of the HLA-Cw gene
----------------------------------

Electrophoretic analysis following the conventional amplification of the HLA-Cw gene revealed that the size of the target fragment was consistent with the expected results ([Fig. 2](#f2-etm-05-01-0300){ref-type="fig"}).

Phenotype and genotype frequencies of HLA-Cw and KIR in the Han population in Jilin
-----------------------------------------------------------------------------------

The results are shown in [Table III](#t3-etm-05-01-0300){ref-type="table"}.

Recognition of HLA-C2^Lys^ and KIR
----------------------------------

The HLA-C2^Lys^ expression frequency was 27.92%, while 72.08 and 21.43% of individuals expressed only KIR2DL1 or KIR2DS1, respectively, without HLA-C2^Lys^. [Table IV](#t4-etm-05-01-0300){ref-type="table"} shows the distribution of the HLA-Cw KIR activating and inhibitory pairing in the Han population of Jilin. The frequency of HLA-C2^Lys80^+2DL1 was 27.27% and that of 2DS1+HLA-C2^Lys80^ was 9.74%. Of the studied individuals, 21.43% expressed only KIR2DS1 without HLA-C2^Lys^-KIR2DL1.

Recognition of HLA-C1^Asn^ KIR
------------------------------

The HLA-C1^Asn80^ expression frequency was 79.87%, notably higher than the expression frequency of HLA-C2^Lys80^ which was 27.92%, while 34.42% of individuals expressed only HLA-C1^Asn^ without iKIR or sKIR. [Table IV](#t4-etm-05-01-0300){ref-type="table"} shows the distribution of the HLA-Cw KIR activating and inhibitory pairings in the Han population of Jilin. The frequency of HLA-C1^Asn80^+2DL2/2DL3 was 68.83% and that of 2DS2+HLA-C1^Asn80^ was 9.74%. Of the studied individuals, 2.60% expressed only KIR2DS2 without HLA-C1^Asn^-KIR2DL2/L3.

Discussion
==========

NK cells recognize virus-infected tissue and tumor cells, then modulate the immune response by killing the target cells through cytotoxic effects or secreting cytokines. NK cells constitute the first barrier of the human immune system ([@b13-etm-05-01-0300],[@b14-etm-05-01-0300]). Immature NK cells must be 'educated' by the MHC HLA-Class I molecules, in order to become mature NK cells ([@b15-etm-05-01-0300]). NK cells adjust their functional status precisely through inhibiting or activating receptors on the membrane surface. In the long-term coevolution of the KIR and the HLA, now highly efficient and accurate receptor-ligand system is formed gradually. ([@b16-etm-05-01-0300]). Previously, in a study of 477 cases of malaria, Hirayasu *et al*([@b17-etm-05-01-0300]) observed that there was a marked correlation between the KIR2DL3 gene and its ligand HLA-C1 in the cerebral malaria patients compared with non-cerebral malaria patients. Further research revealed that the frequency of the combination of the KIR2DL3-HLA-C1 in the malaria high-risk population was maintained at a low level.

Thus, the KIR and HLA combination system is important in regulating NK cell function. Therefore, determining the method of recognition of the HLA-Cw and KIR is particularly important. A total of 154 Han individuals from Jilin were selected. The KIR and HLA-Cw genotyping results revealed that the expression frequency of HLA-C1^Asn80^ was 79.87%, lower than the 97.5% of a Han population in Guangdong ([@b18-etm-05-01-0300]) and the 76% of a population in Iran ([@b12-etm-05-01-0300]). The expression frequency of HLA-C2^Lys80^ in the Han population of Jilin was 27.92%, which was equal to that of the Guangdong Han population ([@b18-etm-05-01-0300]) and lower than the frequency in the Iranian population ([@b12-etm-05-01-0300]). The frequency of HLA-C1^Asn80^ in the Guangdong Han population was 97.5%, which was significantly higher than that of the Jilin Han population. Compared with other populations, the combination frequency of the KIR receptor and its ligand in the Jilin Han population was essentially the same. The frequency of KIR2DS2+HLA-C1^Asn80^ in the Han population of Jilin was 9.74%, less than that of the Guangdong Han (14%) and Iranian (21.5%) populations. The Jilin Han HLA-C1^Asn80^+KIR2DL2/2DL3 frequency was 68.83%, higher than in the Guangdong Han (41.8%) and Iranian (6.5%) populations. These observations may be due to ethnic and regional differences of the HLA and KIR.

In the 154 Han individuals from Jilin, it was also observed that 9.74% of individuals expressed only the combination of 2DS2+HLA-C1^Asn80^ and 9.74% expressed only the combination of 2DS1+HLA-C2^Lys80^. For these individuals, due to the inhibitory signal being unable to completely block the activation of signal transduction, their NK cells may attack other tissues, resulting in autoimmune diseases ([@b10-etm-05-01-0300]). However, this has yet to be confirmed in patients through larger sample and clinical experiments.

Martin *et al*([@b9-etm-05-01-0300]) suggested that the ligands of sKIRs may not be HLA antigens, but bacterial proteins. The authors observed that the KIR2DL1 and KIR2DL2/L3 frequency was high, up to 100%. Therefore the individual expression of HLA-Cw indicates that a corresponding inhibitory ligand receptor is activated. NK cells with sKIR lacking a corresponding HLA-Cw (for example, KIR2DS1 without HLA-Cw2^Lys^) may be activated by bacterial proteins, resulting in autoimmune diseases. In the current study, 21.43% of individuals were observed to express KIR2DS1 without HLA-Cw2^Lys^ inhibitory receptor ligands. Due to the expression frequency of HLA-Cw1^Asn^ being up to 79.87%, no expression of KIR2DS2 only was observed. However, 2.60% of the population expressed KIR2DS2 but not HLA-Cw1^Asn^ inhibitory receptor ligands. The susceptibility to autoimmune disease of such individuals is worthy of investigation.
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![KIR genotyping by PCR-SSP. Lanes 1-16, the PCR-SSP products of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1, KIR2DP1, KIR2DS1 and KIR3DP1, respectively; M, Marker 2000; KIR, killer cell immunoglobulin-like receptor.](ETM-05-01-0300-g00){#f1-etm-05-01-0300}

![HLA-Cw genotyping by PCR-SSP. M, Marker 2000; C1, PCR-SSP products of HLA-Cw1^Asn^; C2, PCR-SSP products of HLA-Cw2^Lys^; HLA-Cw, human leukocyte antigen-Cw.](ETM-05-01-0300-g01){#f2-etm-05-01-0300}

###### 

Primers used for KIR genotyping by PCR-SSP.

  Gene   Primer                     Sequence                  Primer                    Sequence                   Size (bp)
  ------ -------------------------- ------------------------- ------------------------- -------------------------- -----------
  2DL1   F1                         GTTGGTCAGATGTCATGTTTGAA   R1                        GGTCCCTGCCAGGTCTTGCG       146
  F2     TGGACCAAGAGTCTGCAGGA       R2                        TGTTGTCTCCCTAGAAGACG      330                        
  2DL2   F1                         CTGGCCCACCCAGGTCG         R1                        GGACCGATGGAGAAGTTGGCT      173
  F2     GAGGGGGAGGCCCATGAAT        R2                        TCGAGTTTGACCACTCGTAT      151                        
  2DL3   F1                         CTTCATCGCTGGTGCTG         R1                        AGGCTCTTGGTCCATTACAA       550
  F2     TCCTTCATCGCTGGTGCTG        R2                        GGCAGGAGACAACTTTGGATCA    800                        
  2DL4   F1                         CAGGACAAGCCCTTCTGC        R1                        CTGGGTGCCGACCACT           254
  F2     ACCTTCGCTTACAGCCCG         R2                        CCTCACCTGTGACAGAAACAG     288                        
  2DS2   F1                         TTCTGCACAGAGAGGGGAAGTA    R1                        GGGTCACTGGGAGCTGACAA       175
  F2     CGGGCCCCACGGTTT            R2                        GGTCACTCGAGTTTGACCACTCA   240                        
  2DS3   F1                         TGGCCCACCCAGGTCG          R1                        TGAAAACTGATAGGGGGAGTGAGG   242
  F2     CATTGACATGTACCATCTATCCAC   R2                        AAGCAGTGGGTCACTTGAC       190                        
  2DS5   F1                         TGATGGGGTCTCCAAGGG        R1                        TCCAGAGGGTCACTGGGC         126
  F2     ACAGAGAGGGGACGTTTAACC      R2                        ATGTCCAGAGGGTCACTGGG      178                        
  3DL1   F1                         CGCTGTGGTGCCTCGA          R1                        GGTGTGAACCCCGACATG         191
  F2     CCCTGGTGAAATCAGGAGAGAG     R2                        TGTAGGTCCCTGCAAGGGCAA     186                        
  3DL2   F1                         CAAACCCTTCCTGTCTGCCC      R1                        GTGCCGACCACCCAGTGA         211
  F2     CCCATGAACGTAGGCTCCG        R2                        CACACGCAGGGCAGGG          130                        
  3DS1   F1                         AGCCTGCAGGGAACAGAAG       R1                        GCCTGACTGTGGTGCTCG         300
  F2     CCTGGTGAAATCAGGAGAGAG      R2                        GTCCCTGCAAGGGCAC          180                        
  3DL3   F1                         GTCAGGACAAGCCCTTCCTC      R1                        GAGTGTGGGTGTGAACTGCA       232
  F2     TTCTGCACAGAGAGGGGATCA      R2                        GAGCCGACAACTCATAGGGTA     165                        
  2DL5   F1                         GCGCTGTGGTGCCTCG          R1                        GACCACTCAATGGGGGAGC        214
  F2     TGCAGCTCCAGGAGCTCA         R2                        GGGTCTGACCACTCATAGGGT     191                        
  2DP1   F1                         GTCTGCCTGGCCCAGCT         R1                        GTGTGAACCCCGACATCTGTAC     205
  F2     CCATCGGTCCCATGATGG         R2                        CACTGGGAGCTGACAACTGATG    89                         
  2DS1   F1                         CTTCTCCATCAGTCGCATGAA     R1                        AGAGGGTCACTGGGAGCTGAC      102
  F2     CTTCTCCATCAGTCGCATGAG                                                                                     
  2DS4   F1                         CTGGCCCTCCCAGGTCA         R1                        TCTGTAGGTTCCTGCAAGGACAG    204
  F2     GTTCAGGCAGGAGAGAAT         R2                        GTTTGACCACTCGTAGGGAGC     197/219                    
  3DP1   F1                         GGTGTGGTAGGAGCCTTAG       R1                        GAAAACGGTGTTTCGGAATAC      280
  F2     CGTCACCCTCCCATGATGTA                                                           395                        

KIR, killer cell immunoglobulin-like receptor; F1/F2, forward primers; R1/R2, reverse primers.

###### 

Primers used for HLA-Cw genotyping by PCR-SSP.

                  Forward primers   Reverse primers                               
  --------------- ----------------- -------------------- --- -------------------- -----
  HLA-C1^Asn80^   F                 GAGGTGCCCGCCCGGCGA   R   CGCGCAGGTTCCGCAGGC   332
  HLA-C2^Lys80^   F                 GAGGTGCCCGCCCGGCGA   R   CGCGCAGTTTCCGCAGGT   332

HLA-Cw, human leukocyte antigen-Cw; Asn, asparagine; Lys, lysine.

###### 

Phenotype and genotype frequency of KIR and HLA-Cw in the Jilin Han population.

  Gene                Number   Phenotype frequency (%)   Genotype frequency
  ------------------- -------- ------------------------- --------------------
  2DL1                153      99.351                    0.919
  2DL2                21       13.636                    0.071
  2DL3                153      99.351                    0.919
  2DL4                154      100                       1
  2DL5                49       31.818                    0.174
  3DL1                143      92.857                    0.733
  3DL2                154      100                       1
  3DL3                154      100                       1
  2DS2                19       12.338                    0.064
  2DS3                18       11.688                    0.06
  2DS5                37       24.026                    0.128
  3DS1                43       27.922                    0.151
  2DP1                153      99.351                    0.919
  2DS1                48       31.169                    0.17
  3DP1\*003           76       49.351                    0.288
  3DP1\*001/002/004   153      99.351                    0.919
  2DS4\*001/002       113      73.377                    0.484
  2DS4\*003-007       72       46.753                    0.27
  HLA-C1^Asn80^       123      79.87                     0.551
  HLA-C2^Lys80^       43       27.922                    0.151

KIR, killer cell immunoglobulin-like receptor; HLA-Cw, human leukocyte antigen-Cw; Asn, asparagine; Lys, lysine.

###### 

The combined frequencies of various compound KIR-HLA genetypes in the Jilin Han population.

  iKIR+HLA                  Frequency (%)   sKIR+HLA             Frequency (%)
  ------------------------- --------------- -------------------- ---------------
  HLA-C1^Asn80^+2DL2/2DL3   68.83           2DS2+HLA-C1^Asn80^   9.74
  HLA-C2^Lys80^+2DL1        27.27           2DS1+HLA-C2^Lys80^   9.74

KIR, killer cell immunoglobulin-like receptor; iKIR, inhibitory KIR; sKir, stimulatory KIR; HLA, human leukocyte antigen; Asn, asparagine; Lys, lysine.
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